Management of severe COVID-19 in the ICU

Résumé fourni par la source

COVID-19 management in the ICU has been significantly improved due to the evidence that has become available, since the beginning of the pandemic. Among other factors, this has improved outcomes and has increased ICU survival rates. This chapter provides a thorough and up-to-date overview of COVID-19 management in critical care settings. It describes the epidemiology of severe disease and the criteria that define this entity. Additionally, this chapter presents the most updated evidence on specific clinical manifestations, on clinical and laboratory monitoring and on different aspects of severe COVID-19 management, including the sedation and analgesia, the ventilation and oxygenation, the use of ECMO, the haemodynamic monitoring and support, and the pharmacological interventions that are indicated in COVID-19 patients requiring ICU admission. Finally, it discusses usual and more rare complications that are seen in this population and concludes by describing specific long-term complications that ICU survivors develop after ICU discharge. Cite as: Koulenti D, Almyroudi M-P, Andrianopoulos I, et al. Management of severe COVID-19 in the ICU. In: Chalmers JD, Cilloniz C, Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024; pp. 122–152 [ https://doi.org/10.1183/2312508X.10020523 ].

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.